Profile data is unavailable for this security.
About the company
Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.
- Revenue in EUR (TTM)38.18m
- Net income in EUR-28.89m
- Incorporated1999
- Employees159.00
- LocationGenfit SAParc Eurasante 885 avenue Eugene AvineeLOOS 59120FranceFRA
- Phone+33 320164000
- Fax+33 320164001
- Websitehttps://www.genfit.fr/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AB Science SA | 777.00k | -16.89m | 103.62m | 89.00 | -- | -- | -- | 133.36 | -0.3561 | -0.3561 | 0.0164 | -0.3879 | 0.0284 | 0.394 | 2.50 | 7,471.15 | -61.64 | -70.81 | -237.22 | -316.63 | 88.16 | 91.37 | -2,173.10 | -1,225.49 | 1.41 | -- | 135.44 | -- | -40.39 | -11.24 | 5.86 | -- | 5.07 | -- |
| Maat Pharma SA | 2.23m | -19.72m | 103.85m | 50.00 | -- | 5.07 | -- | 46.61 | -1.73 | -1.73 | 0.196 | 1.76 | 0.0508 | 4.84 | 4.16 | 44,560.00 | -44.99 | -35.49 | -58.93 | -42.98 | 74.28 | -- | -884.96 | -1,157.54 | 2.76 | -49.61 | 0.4075 | -- | 55.80 | -- | -43.78 | -- | 30.30 | -- |
| Ose Immunotherapeutics SA | 2.23m | -23.00m | 108.84m | 62.00 | -- | 4.70 | -- | 48.87 | -1.18 | -1.18 | 0.1166 | 1.06 | 0.0256 | -- | 3.22 | -- | -26.46 | -17.17 | -33.15 | -20.55 | -- | -- | -1,032.87 | -94.71 | -- | -97.81 | 0.6659 | -- | -87.83 | -38.07 | -29.52 | -- | -17.11 | -- |
| Eurofins-Cerep SA | 46.17m | 9.21m | 109.96m | 233.00 | 11.94 | 1.83 | 9.82 | 2.38 | 1,826.41 | 1,826.41 | 9,160.00 | 11,939.29 | 0.6814 | 1.66 | 6.04 | 220,892.00 | 13.60 | 15.19 | 16.06 | 18.94 | 85.57 | 67.30 | 19.95 | 19.72 | 5.17 | 112.42 | 0.00005 | 0.00 | 14.45 | 14.30 | 17.09 | 24.52 | -- | -- |
| Adocia SA | 5.73m | -20.55m | 120.24m | 100.00 | -- | -- | -- | 21.00 | -2.36 | -2.36 | 0.6532 | -1.90 | 0.1823 | -- | 16.79 | 55,048.08 | -65.43 | -25.65 | -341.43 | -37.22 | -- | -- | -358.85 | -101.11 | 0.5924 | -2.78 | 2.81 | -- | 692.73 | -10.08 | 69.67 | -- | -40.08 | -- |
| DBV Technologies SA | 4.93m | -95.24m | 121.05m | 88.00 | -- | 0.7815 | -- | 24.53 | -1.01 | -1.01 | 0.0524 | 1.61 | 0.0209 | -- | 0.3738 | 71,517.02 | -40.35 | -64.67 | -46.22 | -80.94 | -- | 91.59 | -1,929.97 | -1,345.10 | -- | -- | 0.0128 | -- | -15.14 | -18.45 | 2.08 | -- | -38.41 | -- |
| Transgene SA | 7.63m | -22.33m | 146.84m | 158.00 | -- | 9.38 | -- | 19.24 | -0.2227 | -0.2227 | 0.0759 | 0.1553 | 0.1368 | -- | 4.28 | 48,316.46 | -40.00 | -24.81 | -50.27 | -29.79 | -- | -- | -292.48 | -193.24 | -- | -- | 0.4764 | -- | -23.68 | 1.51 | 31.94 | -- | 14.44 | -- |
| Eurobio Scientific SA | 128.01m | 7.91m | 152.09m | 304.00 | 19.65 | 0.9605 | 6.24 | 1.19 | 0.7552 | 0.7552 | 11.91 | 15.45 | 0.4856 | 3.75 | 4.48 | 948,222.30 | 3.00 | 21.70 | 3.53 | 28.79 | 45.28 | 50.59 | 6.18 | 25.06 | 2.70 | 4.11 | 0.3799 | 0.00 | -17.38 | 29.03 | -58.81 | -- | -6.24 | -- |
| Genfit SA | 38.18m | -28.89m | 158.72m | 159.00 | -- | 2.34 | -- | 4.16 | -0.5814 | -0.5814 | 0.7681 | 1.36 | 0.1961 | 542.00 | 3.52 | 240,100.60 | -14.84 | -12.57 | -18.55 | -15.30 | 94.32 | 94.96 | -75.69 | -76.23 | 2.94 | -7.78 | 0.5080 | -- | 43.70 | 38.49 | -21.82 | -- | -3.27 | -- |
| Inventiva SA | 17.48m | -110.43m | 165.83m | 112.00 | -- | -- | -- | 9.49 | -2.45 | -2.45 | 0.3854 | -0.6146 | 0.1884 | -- | 9.18 | 156,044.60 | -116.84 | -54.30 | -207.08 | -69.98 | -- | -- | -620.31 | -669.97 | 0.9524 | -19.98 | 6.96 | -- | 43.50 | 40.46 | -103.46 | -- | -0.33 | -- |
| Cellectis SA | 22.94m | -55.71m | 170.14m | -- | -- | 1.84 | -- | 7.42 | -1.06 | -1.56 | 0.445 | 1.29 | 0.0998 | -- | 40.86 | -- | -27.15 | -21.38 | -34.66 | -26.37 | -- | -61.60 | -272.10 | -268.89 | -- | -4.96 | 0.5559 | -- | -33.35 | -5.27 | -5.77 | -- | -14.21 | -- |
| Aelis Farma SA | 5.55m | -5.57m | 172.35m | 22.00 | -- | 10.02 | -- | 31.04 | -0.4123 | -0.4123 | 0.4187 | 1.30 | 0.1405 | -- | 1.36 | 252,409.10 | -14.09 | -30.28 | -22.24 | -49.56 | -- | -- | -100.29 | -168.22 | 2.41 | -- | 0.1337 | -- | -58.03 | -- | -2,589.20 | -- | -- | -- |
| Innate Pharma SA | 51.90m | -7.57m | 173.85m | 179.00 | -- | 3.35 | -- | 3.35 | -0.0939 | -0.0939 | 0.6451 | 0.642 | 0.2648 | -- | 5.67 | 289,949.70 | -3.86 | -8.83 | -4.87 | -12.11 | 94.50 | 93.17 | -14.59 | -55.55 | -- | -- | 0.6408 | -- | 4.68 | -8.27 | 86.94 | -- | 10.50 | -- |
| Sensorion SA | 0.00 | -22.06m | 219.78m | 50.00 | -- | 4.12 | -- | -- | -0.2063 | -0.2063 | 0.00 | 0.1779 | 0.00 | -- | -- | -- | -51.64 | -35.12 | -71.66 | -46.97 | -- | -- | -- | -- | -- | -- | 0.0794 | -- | -- | -- | 4.94 | -- | 126.45 | -- |
Data as of Apr 19 2024. Currency figures normalised to Genfit SA's reporting currency: Euro EUR
6.23%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tang Capital Management LLCas of 06 Jul 2023 | 2.45m | 4.92% |
| Healthinvest Partners ABas of 30 Jun 2022 | 325.00k | 0.65% |
| Sunny Asset Management SAas of 27 Mar 2024 | 120.00k | 0.24% |
| Lazard Asset Management LLCas of 31 Dec 2022 | 39.36k | 0.08% |
| Meeschaert Asset Management SAas of 14 Sep 2023 | 37.91k | 0.08% |
| OFI Invest Asset Management SAas of 29 Feb 2024 | 31.13k | 0.06% |
| Clay Asset Management SASas of 30 Jun 2023 | 30.00k | 0.06% |
| American Century Investment Management, Inc.as of 04 Apr 2024 | 24.98k | 0.05% |
| Mandarine Gestion SAas of 30 Jun 2023 | 24.00k | 0.05% |
| Alphajet Fair Investors SASas of 09 Apr 2024 | 20.00k | 0.04% |
More ▼
Data from 30 Jun 2023 - 09 Apr 2024Source: FactSet Research Systems Inc.
